Seasonal Malaria Chemoprevention Rapid Assessment Study Mozambique

Launched by MALARIA CONSORTIUM · Mar 22, 2024

Keywords

ClinConnect Summary

The Seasonal Malaria Chemoprevention Rapid Assessment Study in Mozambique is looking at a way to prevent malaria, specifically the type caused by Plasmodium falciparum, which is common in areas where malaria spreads during certain seasons. The study will test a combination of two medications, sulfadoxine-pyrimethamine and amodiaquine (SP+AQ), to see how well they work in preventing malaria in children aged 3 to 59 months in Niassa Province. Researchers want to understand not just how effective these medicines are, but also how acceptable and feasible this prevention method is for families in the area.

To participate in this study, children need to be between 3 and 59 months old, and their parents must provide written consent. The study will gather information from two parts: one will focus on measuring how well the medicines work, while the other will explore how families feel about and can use this prevention method. This research could help shape future health policies and potentially expand successful malaria prevention strategies beyond the Sahel region, helping more communities protect their children from malaria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Within 3 to 59 months
• • Parents have provided written consent
• Exclusion Criteria:
• • Outside 3 to 59 months or age
• • Parents have not provided written consent